DETAILED NOTES ON ABBV-744 BRD4 INHIBITOR MECHANISM OF ACTION

In Segment A, contributors will get diverse doses and schedules of oral ABBV-744 tablet to identify safe dosing routine. Extra contributors are going to be enrolled for the recognized monotherapy dosign program. In Section B, participants will get oral ruxolitinib and ABBV-744 is going to be given as "increase-on" therapy. In Segment C, contributor